In type 2 diabetes, tirzepatide reduced HbA1c vs. semaglutide

Ann Intern Med. 2021 Nov;174(11):JC127. doi: 10.7326/ACPJ202111160-127. Epub 2021 Nov 2.

Abstract

Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503-15. 34170647.

Publication types

  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2* / drug therapy
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptides
  • Glycated Hemoglobin / analysis
  • Humans
  • Hypoglycemic Agents / therapeutic use

Substances

  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • semaglutide
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptides
  • tirzepatide